Immunogenicity, Safety, and Persistence Induced by Triple- and Standard-Strength 4-Dose Hepatitis B Vaccination Regimens in Patients Receiving Hemodialysis - Takeaways - MDSpire

Immunogenicity, Safety, and Persistence Induced by Triple- and Standard-Strength 4-Dose Hepatitis B Vaccination Regimens in Patients Receiving Hemodialysis

  • By

  • Tian Yao

  • Yandi Li

  • Yidan Zhang

  • Yangle Sun

  • Yana Guo

  • Jianmin Wang

  • Xiaohui Song

  • Wei Zhang

  • Baozhu Wei

  • Jingen Bai

  • Hui Wang

  • Weimin Yu

  • Huiyuan Wang

  • Lu Jiao

  • Yinqiang Diao

  • Liming Liu

  • Shuaishuai Shi

  • Jie Yang

  • Xiaojun Ren

  • Wenyuan Liu

  • Jingai Fang

  • Xiaofeng Liang

  • Suping Wang

  • Yongliang Feng

  • October 8, 2024

  • 0 min

Share

  • 1

    The study evaluated the immunogenic response, safety, and longevity of different hepatitis B vaccination regimens in hemodialysis patients.

  • 2

    A total of 504 hemodialysis patients were enrolled and randomly assigned to receive three different hepatitis B vaccine schedules.

  • 3

    The triple-strength 4-dose regimen (60 μg) demonstrated superior immunogenicity and longer duration of protective antibodies compared to standard regimens.

  • 4

    Response rates of anti-HBs decreased significantly over time, with the triple-strength group maintaining protective antibodies for 29.2 months.

  • 5

    All adverse reactions to the vaccination were mild, indicating that the triple-strength regimen is safe for hemodialysis patients.

Original Source(s)

Related Content